financetom
VERA
financetom
/
Healthcare
/
VERA
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Vera Therapeutics, Inc.VERA
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.

Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis.

It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020.

Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Latest News >
Schlumberger, Palo Alto Networks Expand Partnership to Enhance Cybersecurity for Energy Industry
Schlumberger, Palo Alto Networks Expand Partnership to Enhance Cybersecurity for Energy Industry
Aug 19, 2024
08:59 AM EDT, 08/19/2024 (MT Newswires) -- Schlumberger ( SLB ) and Palo Alto Networks ( PANW ) are expanding their partnership to enhance cybersecurity for the energy industry, the companies said Monday. Under the terms, the firms will integrate Schlumberger's ( SLB ) domain, cloud, and edge technologies in the energy sector with Palo Alto's platform-based cybersecurity services, the...
Sector Update: Financial
Sector Update: Financial
Aug 19, 2024
08:59 AM EDT, 08/19/2024 (MT Newswires) -- Financial stocks were edging higher pre-bell Monday with the Financial Select Sector SPDR Fund (XLF) up 0.1% recently. B. Riley Financial ( RILY ) shares were down more than 8% after saying its Chair and Co-Chief Executive Bryant Riley has made an unsolicited proposal to take the company private for $7 per share....
Alzamend Neuro Enters Partnership for Phase II Clinical Trial of Potential Lithium Therapeutic Drug for Post-Traumatic Stress Disorder; Shares Soar
Alzamend Neuro Enters Partnership for Phase II Clinical Trial of Potential Lithium Therapeutic Drug for Post-Traumatic Stress Disorder; Shares Soar
Aug 19, 2024
08:59 AM EDT, 08/19/2024 (MT Newswires) -- Alzamend Neuro ( ALZN ) said Monday it is teaming up with Massachusetts General Hospital for a phase II clinical trial of its lithium therapeutic drug candidate for post-traumatic stress disorder. The study of AL001 aims to compare the increase in lithium levels within the brain and its structures versus a commonly marketed...
Sector Update: Tech
Sector Update: Tech
Aug 19, 2024
08:47 AM EDT, 08/19/2024 (MT Newswires) -- Technology stocks were steady premarket Monday, with the SPDR S&P Semiconductor ETF (XSD) inactive and the Technology Select Sector SPDR Fund (XLK) was slightly higher recently. Advanced Micro Devices ( AMD ) shares were up more than 2% after saying it has agreed to acquire artificial intelligence infrastructure provider ZT Systems in a...
Copyright 2023-2025 - www.financetom.com All Rights Reserved